Lexaria Bioscience Corp Stock Price, News & Analysis

Lexaria Bioscience Corp. (NASDAQ: LEXX) has provided an update on its Material Transfer Agreement (MTA) with an unnamed pharmaceutical company (PharmaCO). The company has completed initial pre-clinical pharmacokinetic animal studies evaluating Lexaria's DehydraTECHTM technology, though results will remain confidential. PharmaCO has expressed interest in reviewing pending safety and efficacy data from Lexaria's ongoing independent human study GLP-1-H24-4 in Australia, expected in Q3 2025.

Lexaria is preparing for strategic planning discussions with PharmaCO's human clinical development team regarding potential collaborative human clinical studies. Both parties have agreed to maintain their relationship and keep the temporary exclusive license active until the Australian study data becomes available.

Lexaria Bioscience (NASDAQ: LEXX) has successfully closed a $2 million registered direct offering of common stock with a single institutional investor. The deal was structured at $1.00 per share for 2,000,000 shares, with an option for pre-funded warrants in lieu of shares.

Key highlights of the offering:

• H.C. Wainwright & Co. served as the exclusive placement agent
• The offering was made under an effective S-3 shelf registration
• No additional warrants were issued except for pre-funded warrants
• Net proceeds will support working capital and general corporate purposes

CEO Richard Christopher emphasized the achievement of securing funding in challenging market conditions while minimizing shareholder dilution by avoiding additional warrant issuance. The offering was completed through a shelf registration statement that received SEC approval on January 30, 2025.

Lexaria Bioscience (NASDAQ:LEXX) has secured a definitive agreement with a single institutional investor for a $2 million registered direct offering of common stock. The deal involves the sale of 2,000,000 shares at $1.00 per share.

The offering, expected to close around April 28, 2025, is being facilitated by H.C. Wainwright & Co. as the exclusive placement agent. The company plans to utilize the net proceeds, after deducting placement agent fees and offering expenses, for working capital and general corporate purposes.

The offering is being conducted under Lexaria's effective S-3 shelf registration statement, with a final prospectus supplement and accompanying prospectus to be filed with the SEC.

Lexaria Bioscience (NASDAQ:LEXX) provides a strategic update on GLP-1 industry developments, highlighting its DehydraTECH technology's potential in enhancing oral drug delivery. Recent industry news includes Pfizer's discontinuation of danuglipron development due to liver injury concerns, while Eli Lilly reported positive phase 3 results for orfoglipron, leading to a $100 billion market valuation increase.

The company emphasizes that DehydraTECH has demonstrated enhanced delivery performance with existing oral GLP-1 drugs and shown potential in reducing common side effects that lead to high discontinuation rates (47-64% within 1-2 years). Lexaria is executing its strategy through collaborations, evidenced by a material transfer agreement with PharmaCO announced in September 2024.

The GLP-1 drug sector is expected to generate over $100 billion in annual revenue, with applications expanding across multiple healthcare sectors including cardiovascular disease, chronic kidney disease, obesity, and diabetes.

Lexaria Bioscience (NASDAQ:LEXX) has announced completion of patient enrollment for its Phase 1b clinical study GLP-1-H24-4 in Australia. The 12-week study, investigating safety, diabetes control, and weight loss, has exceeded its initial enrollment targets with 24 patients per study arm versus the original target of 20, across all 5 study arms.

The achievement marks the 'last patient in' (LPI) milestone, with treatment expected to conclude in approximately twelve weeks. Following the treatment phase, the company will proceed with patient sample analyses, data compilation, analysis, and reporting.

Lexaria Bioscience (NASDAQ:LEXX) has initiated dosing in its human study GLP-1-H25-5, comparing oral DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide. The study focuses on pharmacokinetics and safety assessment.

A previous 12-week rodent study showed that oral DehydraTECH-liraglutide achieved:

• 5.88% weight reduction
• 11.54% blood sugar reduction

Earlier GLP-1 PK studies in humans demonstrated that certain oral DehydraTECH formulations showed superior bloodstream delivery and reduced adverse events compared to existing oral semaglutide and injectable tirzepatide products. Currently, liraglutide is only available as an injectable under Saxenda® and Victoza® brands. Despite Teva's generic version launch in June 2024, Novo Nordisk generated $1.0 billion in Saxenda® revenue and $0.8 billion in Victoza® revenue during 2024.

Lexaria Bioscience (NASDAQ:LEXX) announced positive results from Human Study #3 comparing oral DehydraTECH-tirzepatide capsules to injectable Zepbound®. The study showed that oral capsules achieved comparable blood concentration levels to injections by the study's end.

Key findings from the 8-day study of 19 participants revealed that while injected Zepbound® typically peaked on Day 2 and declined, DehydraTECH-tirzepatide levels increased steadily daily. The oral version demonstrated:

• 47% fewer adverse events (20 vs 38)
• 54% reduction in gastrointestinal side effects
• Similar blood glucose reduction and insulin increase by Day 8

The company is now conducting a 12-week Phase 1b registrational study in Australia, starting at 20mg/day for 4 weeks and escalating to 40mg/day for the remaining 8 weeks. This extended study aims to evaluate steady-state blood levels and potentially demonstrate increased delivery and efficacy.

Lexaria Bioscience (NASDAQ:LEXX) has outlined its triple-pronged strategy in the GLP-1 drug sector, focusing on its DehydraTECH technology. The strategy includes: collaborating with pharmaceutical companies through material transfer agreements; developing patented DehydraTECH-CBD products for GLP-1 applications; and investigating an oral version of liraglutide.

The company's DehydraTECH technology addresses two major challenges in GLP-1 drugs: injection administration and gastrointestinal side effects. Clinical testing has shown DehydraTECH's delivery superiority to Rybelsus, the only existing oral GLP-1 drug. The technology has demonstrated reduced side effects in both tirzepatide and semaglutide.

This development comes as the FDA recently approved Ozempic (semaglutide) for chronic kidney disease treatment in type 2 diabetes patients. The GLP-1 sector is expected to generate over $100 billion in annual revenue, with some forecasts reaching $471 billion.